An elderly man was diagnosed with extensive stage-small cell lung cancer (ES-SCLC) and brain metastases. Approximately 10% of patients with SCLC present with brain metastases at the time of diagnosis. The patient received four lines of treatment. After the fourth line of treatment, he received bevacizumab in combination with irinotecan as a post-fourth-line therapy and achieved a significant partial response. However, brain metastases were found, and the patient underwent stereotactic radiation therapy. In July 2022, a new metastatic lesion was found in the right lung, and the patient received treatment with anlotinib, a novel, orally administered multi-targeting tyrosine kinase inhibitor. At the end of October 2022, a brain magnetic resonance imaging (MRI) showed that the brain.
